Product Code: RP-ID-10151895 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151895
Market Overview:
Global Prenatal Testing and Newborn Screening Industry Market Research 2030
"According to United Nations statistics, more than 131 million babies are born every year in the world. In addition, about 8 million people were born with birth defects. Prenatal testing and newborn screening are one of the advanced technologies used by the healthcare industry to identify defects at an early stage. In the early stages, the use of these tests has greatly increased to identify any birth defects. Screen headphones occupy an important share in the field of musical instruments, with a market share of 25%.
The growth of the prenatal and newborn genetic testing market is mainly due to the understanding of various genetic and chromosomal diseases, which can be detected with the help of advanced equipment, so more action plans can be planned. The development of a variety of healthcare technologies, such as next-generation sequencing and high-throughput screening, is helpful for early detection of various abnormalities. These tests are expected to grow at a compound annual growth rate of 11% during the forecast period (i.e., 2022-2030).
What are antenatal checkups and newborn screening?
Prenatal diagnosis is a series of tests performed during pregnancy to determine the health of the fetus at an early stage. These tests can identify various genetic and chromosomal abnormalities, such as birth defects, genetic mutations, and cystic fibrosis. Prenatal diagnosis aims to detect abnormal diseases early so that appropriate treatment can be recommended.
Newborn screening is a test performed on the first day after birth to detect certain changes that can hinder its growth and development. In these tests, various abnormalities are detected, such as phenylketonuria (PKU), galactosemia, sickle cell anemia, and congenital hypothyroidism. The report provides an in-depth analysis of the prenatal testing and newborn screening market by type, diagnostic technology, technology, instrumentation, and geography.
What are the main applications of antenatal checkups and newborn screening tests?
Prenatal examinations and newborn screening help identify various genetic and chromosomal diseases. With the help of these tests, genetic diseases such as sickle cell anemia, Down syndrome, cystic fibrosis and muscular dystrophy can be detected.
Help provide timely medical or surgical treatment before or after birth. If the fetus is diagnosed with a life-threatening disease, these tests also provide a chance of miscarriage. Help parents prepare psychologically, socially, economically, and medically for babies with health problems. In some cases, extremely rare diseases can also be detected.
Market research and neonatal screening and prenatal testing market trends:
In 2016, Eurofins LifeCodexx launched the first real-time quantitative PCR-based non-invasive prenatal testing (NIPT) test for fetal trisomy 21 prenatal testing. Compared with traditional PCR technology, this test is cost-effective and faster in processing time.
Therefore, it is widely used in molecular diagnostics because the test results have the highest quality standards. In 2017, Eurofins Genome improved the NIPT technology, which uses simple blood tests to detect de novo (non-hereditary gene mutations) and hereditary monogenic diseases. About 60% to 65% of prenatal genetic testing is now moving to the next one. -Generation sequencing method (NGS).
The emergence of NGS, combined with various microarray technologies, provides a broader scope for creating tests with better specificity and sensitivity. G​​​​​​​​​​​​​​​​​​​​​​​ Whole Exome Sequencing (WES) is the analysis of all exons of all protein-coding genes in the human genome. WES is a cheaper and more effective mutation detection method. However, WGS is useful because it analyzes approximately 3 billion base pairs and is more powerful than WES.
Today, WGS is much more expensive than WES due to its sequencing technology, and requires a large database to store, manage, and analyze data. WGS has been improving at a very fast rate, and as costs decrease, it will become more popular than WES in clinical practice. Qiagen, which focuses solely on oncology, has shifted its focus from developing fetal cell-free DNA testing to prenatal testing technology. Pregnant women can undergo non-invasive prenatal check-ups to prevent birth defects in their babies. This technology distinguishes the background of the fetal placental DNA from the mother’s DNA and provides doctors with detailed information about the baby’s genetic problems.
Who are the main players in the prenatal care and newborn screening market?
Companies cited in this market research report include Abbott Laboratories, Thermo Fisher Scientific, Qaigen, Bio-Rad, Strand life sciences, Roche Holding AG, Eurofins Scientific, Natera Inc., Premaitha Health plc, Illumina, and Quest Diagnostics."
Related Reports
Proof of Quality & Reliability
